Daniel Berger, MD
Endocrinology, Diabetes & Metabolism · Santa Barbara, CANPI 1669407680
Payments from drug & device makers
Across 825 payments — averaging $656.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$270K
- AstraZeneca$97K
- Dexcom, Inc.$60K
- Abbott$46K
- Amgen$22K
- Bayer$21K
- plus $25K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 295 | $269,973 |
| AstraZeneca | 128 | $96,767 |
| Dexcom, Inc. | 76 | $60,264 |
| Abbott | 92 | $46,003 |
| Amgen | 47 | $21,700 |
| Bayer | 22 | $21,116 |
| Mannkind Corporation | 30 | $14,000 |
| Johnson & Johnson | 13 | $7,370 |
| Lilly USA, LLC | 12 | $1,064 |
| Xeris Pharmaceuticals, Inc. | 38 | $1,054 |
| Sequel Med Tech, LLC | 13 | $342 |
| Medtronic(2 entities) | 4 | $252 |
| BETA Bionics, Inc. | 6 | $165 |
| Tandem Diabetes Care, Inc. | 3 | $155 |
| Insulet Corporation | 2 | $155 |
| Sanofi-aventis U.S. LLC | 8 | $140 |
| Merck | 7 | $105 |
| AbbVie | 5 | $102 |
| Boehringer Ingelheim | 5 | $98 |
| Novartis | 3 | $98 |
| Amarin Pharma, Inc. | 4 | $62 |
| Antares Pharma, Inc. | 2 | $58 |
| Ascensia Diabetes Care US Inc. | 2 | $33 |
| Eisai Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $11 |
| Cequr Corporation | 1 | $11 |
How this compares
$541,208 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Santa Barbara
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.